2011
DOI: 10.3109/09273948.2011.589022
|View full text |Cite
|
Sign up to set email alerts
|

Rapid and Sustained Resolution of Serous Retinal Detachment in Sturge-Weber Syndrome after Single Injection of Intravitreal Bevacizumab

Abstract: An early single dose of intravitreal bevacizumab is effective in the treatment of serous retinal detachment in SWS with good long-term results.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
10
0

Year Published

2012
2012
2022
2022

Publication Types

Select...
6
4

Relationship

0
10

Authors

Journals

citations
Cited by 22 publications
(11 citation statements)
references
References 5 publications
1
10
0
Order By: Relevance
“…Intralesional Bevacizumab has been reported in the treatment of epistaxis in hereditary haemorrhagic telangiectasia (HHT) and intraorbital hemangiomas [38]. Intravenous Bevacizumab has been reported to be effective in the treatment of AVMs of patients with HHT, in radiation-induced cavernomas and in central nervous system hemangioblastomas [39][40][41][42].…”
Section: Vegf Pathway Inhibitors (Ie Bevacizumab)mentioning
confidence: 98%
“…Intralesional Bevacizumab has been reported in the treatment of epistaxis in hereditary haemorrhagic telangiectasia (HHT) and intraorbital hemangiomas [38]. Intravenous Bevacizumab has been reported to be effective in the treatment of AVMs of patients with HHT, in radiation-induced cavernomas and in central nervous system hemangioblastomas [39][40][41][42].…”
Section: Vegf Pathway Inhibitors (Ie Bevacizumab)mentioning
confidence: 98%
“…[ 43 ] A single intravitreal bevacizumab injection has resulted in sustained resolution of exudative RD in Sturge-Weber syndrome over 20 months in a single case. [ 44 ]…”
Section: Diffuse Choroidal Hemangiomamentioning
confidence: 99%
“…There is no definitive treatment regimen for exudative retinal detachment in patients with choroidal hemangiomas. Treatment options include radiotherapy [ 4 ], photodynamic therapy [ 5 ], oral propranolol [ 6 ], pegaptinib [ 7 ], and bevacizumab [ 8 ],[ 9 ].…”
Section: Introductionmentioning
confidence: 99%